← All trials
NCT06425549
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2024
- Primary completion
- Aug 21, 2028
- Completion date
- Nov 8, 2030
- First posted
- May 22, 2024
- Last posted
- Jul 26, 2024
- Enrollment
- 168
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- UCBLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.